Skip to main content
. 2017 Jul 4;102(10):1718–1726. doi: 10.3324/haematol.2017.171645

Figure 4.

Figure 4

LncRNA XLOC_109948 expression levels can predict clinical outcome. (A) Clinical outcomes in patient subgroups defined according to cut offs (−ΔCt value) and identified with ROC curves for each lncRNA. (B) Prognostic value of XLOC_109948 lncRNA expression in a validation cohort (Cohort 2, n=134) of cytogenetically normal acute myeloid leukemia (CN-AML) patients. Kaplan-Meier plots show the event-free survival (EFS), overall survival (OS) and disease-free survival (DFS) of patient subgroups with high versus low transcript levels of XLOC_109948 lncRNA. (C) Multivariate analyses of clinical outcome in 134 patients (Cohort 2). (D) Risk stratification of patients with CN-AML according to NPM1 mutational status and XLOC_109948 expression level (Cohort 2). EFS, OS and DFS are shown for the four subgroups defined by NPM1 and XLOC_109948 status. P values are given for the overall comparison across all four groups. optcut: optimal cut off; HR: hazard ratio.